Guanhao Biotech Co

Guanhao Biotech Co Current Liabilities

The Current Liabilities of Guanhao Biotech Co (300238.SZ) as of Oct 31, 2026 is 155.94 M CNY. In the previous year, Current Liabilities was 199.28 M CNY — a change of -21.75% (lower).

Current Liabilities

155.94 MCNY

YoY

-21.75%

Last updated:

Current Liabilities of Guanhao Biotech Co is 2025 155.94 M CNY. Current Liabilities of Guanhao Biotech Co was 2024 199.28 M CNY. It decreases by -21.75% lower compared to the previous year.

The Guanhao Biotech Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
164.67 M CNY
Jan 1, 2019
309.31 M CNY
Jan 1, 2020
347.83 M CNY
Jan 1, 2021
193.66 M CNY
Jan 1, 2022
174.24 M CNY
Jan 1, 2023
197.83 M CNY
Jan 1, 2024
199.28 M CNY
Jan 1, 2025
155.94 M CNY
The Guanhao Biotech Co Current Liabilities history
YEARCurrent LiabilitiesYoY
155.94 MCNY-21.75%
199.28 MCNY+0.73%
197.83 MCNY+13.54%
174.24 MCNY-10.03%
193.66 MCNY-44.32%
347.83 MCNY+12.45%
309.31 MCNY+87.84%
164.67 MCNY-63.12%
446.48 MCNY+144.71%
182.46 MCNY+68.99%
107.97 MCNY+203.09%
35.62 MCNY+15.12%
30.94 MCNY-15.48%
36.61 MCNY+248.06%
10.52 MCNY-71.11%
36.41 MCNY+245.86%
10.53 MCNY-15.87%
12.51 MCNY-27.61%
17.28 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guanhao Biotech Co Stock analysis

What does Guanhao Biotech Co do? Guanhao Biotech Co Ltd develops and sells regenerative medical materials and implant devices, including biological dura mater patches, chest general surgery department patching membranes (type P and type B), asepsis biological wound-surface protection membranes, type B dura matrix, and intraocular lenses. The company generates revenue through the sale of these products to healthcare providers and medical institutions. Its primary customers are hospitals and surgical departments requiring advanced regenerative solutions for wound care and ophthalmic procedures. The firm also offers related technological services as part of its product portfolio. The company focuses on regenerative medical applications, targeting segments such as neurosurgery, general surgery, and ophthalmology. Its product range addresses specific clinical needs, including dura mater repair, wound protection, and vision correction. By providing specialized medical materials, Guanhao Biotech serves healthcare facilities seeking innovative solutions for patient recovery and surgical outcomes. Guanhao Biotech's core business revolves around the production and distribution of high-value medical devices and materials. The firm's revenue streams are derived from direct sales of its regenerative medical products and associated technological services. Key segments include hospitals, surgical departments, and ophthalmic clinics that utilize its specialized membranes and lenses for patient care. Guanhao Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guanhao Biotech Co stock

Current Liabilities of Guanhao Biotech Co is 155.94 M CNY in 2025.

Current Liabilities of Guanhao Biotech Co changed from 199.28 M CNY to 155.94 M CNY, representing a -21.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Guanhao Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Guanhao Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Guanhao Biotech Co

All Key Metrics — Guanhao Biotech Co